DYN Dyne Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why DYN matters now
Dyne Therapeutics, Inc. (DYN) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.27 with +1.85% on the session and $4.01B in market capitalization; recent performance reads 1-month +24.37% and YTD +1.23%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-120.9M, and EPS of $-0.73. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -14.1%.
The latest indexable market news headline is "Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $35.50; recent insider activity includes Cox John filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.78
P/S
0.00
EV/EBITDA
-5.88
DCF Value
$6.74
FCF Yield
-14.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-58.3%
ROA
-41.8%
ROIC
-45.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-120.9M | $-0.73 |
| Q4 2025 | $0.00 | $-112.0M | $-0.76 |
| FY 2025 | $0.00 | $-446.2M | $-3.47 |
| Q3 2025 | $0.00 | $-108.0M | $-0.76 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$35.50
Target (Median)
$35.50
Target Range
$24.00 - $47.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.08
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.